All In Biotech

Drug Trial Radar · NCT05644717

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease /Non-Alcoholic Steatohepatitis

Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Mar 1, 2023

Primary completion

Nov 1, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Getz PharmaIndustry
Sponsor type
Industry
First posted
Dec 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)

Conditions

  • Liver Fat
  • Liver Fibrosis
  • Glycemic Control
  • Body Weight Changes
  • Waist Circumference
  • Tolerance

Interventions

  • Ertugliflozin 5 mg, 15mgDrug

    Ertugliflozin 5/15mg once daily in addition to standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiologic liver parametersTime frame: up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • North west general hospital

    Peshawar, KPK, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.